Intercepting Cancer by Tackling Precancer
Many of the most common cancers are heralded by premalignant conditions. Treating premalignancy may prove to be the most promising tactic for cancer interception.
Progress Against Cancer
Many of the most common cancers are heralded by premalignant conditions. Treating premalignancy may prove to be the most promising tactic for cancer interception.
Researchers in Japan observe the rare occurrence of a mother passing cancer cells to their child, and more news of the week from Cancer Today.
The FDA approved the first once-a-day pill to lower the levels of testosterone in certain patients with prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the first oral gonadotropin-releasing hormone (GnRH)...
The FDA approved the molecularly targeted therapeutic selinexor to be used in combination with another targeted agent and a synthetic corticosteroid to treat certain patients with multiple myeloma. The U.S. Food and Drug Administration...
In the early 1970s, German virologist Harald zur Hausen, MD, FAACR, defied the dogma that cervical cancer was caused by the herpes simplex virus (HSV). He proposed that another virus—the human papillomavirus (HPV)—could lead to cervical cancer. While his initial studies...
As the year draws to a close, we bring you the final edition of Editors’ Picks for 2020. This monthly roundup features one “must read” article, handpicked by the editors, from each journal issue published by the AACR. Studies highlighted in this post include a review article...
The U.S. FDA has approved a new targeted therapy for certain patients with HER2-positive breast cancer who were previously treated with other targeted therapies.
New therapies provide hope and options for people as they monitor and manage this incurable blood cancer.
Sophisticated blood tests offer a less invasive way to characterize cancers, guide treatment and catch recurrences sooner, but tissue biopsies remain the gold standard.
Using deep learning to detect tumor mutations.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More